摘要
银屑病是一种免疫介导的慢性炎症性疾病,病因及发病机制涉及遗传、免疫、环境等多种因素;该病也是一种系统性疾病,严重影响患者的身心健康。近年来的研究证明:白介素-17(IL-17)与银屑病的免疫学发病机制密切相关,在银屑病的发生、发展中发挥关键作用。具有选择性靶向IL-17A及其受体的生物制剂已开始应用于临床,并显示了良好的疗效与安全性,为银屑病的治疗提供了新策略。
Psoriasis is an immune-mediated chronic inflammatory disease,and genetic,immunological,environmental and other factors are involved in its etiology and pathogenesis.As a systemic disease,psoriasis severely aggravates the physical and mental health of patients. In recent years,studies have proved that interleukin-17（ IL-17） is closely related to the immunological pathogenesis of psoriasis,and plays a key role in the occurrence and development of psoriasis. Biological agents selectively targeting IL-17A and its receptors have been used clinically and showed satisfactory curative effect and safety,which provides new strategies for the therapy of psoriasis.
出处
《皮肤科学通报》
2018年第1期43-50,共8页
Dermatology Bulletin
